Jiayu Bio Completes $10M Series B Financing to Advance Integrated Biologics Testing and Quality Outsourcing Services
VCBeat has learned thatRecently, JADE Biomedical announced the completion of its Series B financing round.This round of financing is led by a well-known investment institution in Hong KongDingpei Group(VMS Group) led the investment,Ruifu Medical Venture Capital Fund(Panacea Venture) co-invested. The funds raised in this round will be used for the procurement of instruments, equipment, reagents, and consumables to expand the GMP testing services for biologics, as well as to cover costs related to recruitment, corporate operations, and the acquisition of technical patents.
Dr. Claudia Lin, Founder, Chairman, and CEO of JADE Biomedical, stated:Over the past five years, JADE Biomedical has had the privilege of serving more than 50 highly accomplished leading biopharmaceutical companies both domestically and internationally. Amidst a challenging environment marked by stringent rectification in the biopharmaceutical industry and other adverse factors, JADE Biomedical has once again earned the recognition of VMS Group and Panacea Venture—professional investment institutions with an international perspective specializing in R&D and industrialization of innovative biological drugs. This Series B financing will significantly bolster the rapid development of JADE’s testing business in its next phase, laying a solid foundation for its comprehensive GMP-compliant testing services for large-molecule biologics, including cell and gene therapy products, aligned with international standards.This round of financing builds upon JADE’s strategic partnership with Charles River Laboratories, a global CXO giant in the biopharmaceutical sector. It fully leverages the industry-leading position of international corporations combined with JADE’s extensive experience navigating China’s local regulatory landscape. This synergy holds unique and critical significance for enabling Chinese innovative biologics to enter advanced international markets through JADE’s distinctive niche in biological drug quality services.I firmly believe that the next five years will mark a new stage for JADE Biomedical to expand and comprehensively strengthen its presence in this specialized and scarce sector. We remain committed to upholding international GMP quality service standards, closely keeping pace with high-end biological drug R&D trends both domestically and globally, and striving tirelessly for the health of people in China and around the world. With the support of our existing and new partners, we are filled with confidence in the future.
Mr. Wu Zhaowei, Managing Director and Head of Healthcare Investments at VMS Group, and Partner at Ruifu Medical Venture Capital, stated:JADE Biomedical provides end-to-end quality and testing technical services to global high-end biopharmaceutical companies, particularly those in the cell and gene therapy (C>) sector, holding a leadership position in the rapidly growing field of outsourced bioquality and testing services. We are honored to lead this round of financing and remain committed to investing in companies with breakthrough technologies and high-growth potential. We are confident that, under the leadership of the founding team, the company will continue to achieve rapid development and stand out in the outsourced quality services market for biologics in China and globally.
JADE Biomedical was established in June 2017, and isThe First OneProposing Bio-CQO®, a company pioneering the novel business model of contracted services for biologic drug quality and holding registered trademarks. Over the past five years, JADE Biomedical has successfully assisted clients in delivering IND-to-BLA filings for more than 50 projects within GMP quality systems and product QA/QC/QV, as well as related regulatory registration and submission services. These clients include leading Chinese and U.S. enterprises in the industrialization of large-molecule biologics—such as companies specializing in monoclonal antibodies, ADCs, CAR-T and other CGT products, and mRNA therapies—as well as leading CDMOs in China and the United States.
At the end of 2020, JADE Biomedical established a strategic partnership with Charles River Laboratories (CRL), a global top 10 CXO. JADE Biomedical is the only CXO company in China to have earned CRL’s trust, received its Series A investment, and entered into a strategic partnership. JADE Biomedical’s integrated biopharmaceutical testing laboratory in China has been certified by CRL as an unrestricted third-party contractor for its global GMP testing of biologics.
JADE Biomedical’s biopharmaceutical testing laboratory specializes in quality control testing services and comprehensive GMP cell bank operations, ensuring compliance with Good Manufacturing Practice (GMP) requirements and pharmacopoeial standards in China, the United States, and Europe.Testing services span from cell banks, culture media, plasmids, viruses, intermediates, to final products. Our methodological platforms encompass microbiological testing, mycoplasma testing, and viral testing (including endogenous and exogenous viruses, Replication-Competent Lentivirus [RCL]), various nucleic acid tests, as well as potency assays and biological residue analysis. All clients commissioning JADE Biomedical for testing can also benefit from our professional one-stop guidance and agency services for the import and export declaration of biological samples, integrated with JADE’s Bio-CQO.®JADE Biomedical’s cold chain management and testing services are at the forefront in China in terms of brand, professionalism, compliance, internationalization, and leadership team. It provides GMP quality management services covering the entire industry chain, safeguarding the R&D and industrialization of China’s biopharmaceutical industry, particularly its entry into advanced pharmaceutical markets in Europe and the United States.
Dingpei Group, established in 2006, is a leading diversified financial group that provides professional and diverse investment solutions and advisory services through its subsidiaries. Its business scope covers private equity, corporate financing, structured financing, real estate investment, and securities trading. In the realm of private equity, the group focuses on innovation and growth opportunities in key sectors such as healthcare, technology, media and telecommunications (including new retail and new services), and frontier technologies. The Dingpei Healthcare team is dedicated to identifying outstanding global innovative healthcare companies that address unmet clinical needs, with investment areas spanning pharmaceuticals, medical devices, diagnostics, and CXO services. To date, Dingpei Group has successfully completed over 150 investments both within and outside China.
Panacea Venture is a venture capital firm focused on the healthcare industry, with offices in Shanghai, Hong Kong, and Silicon Valley. Founded in 2017, Panacea Venture specializes in investing in and incubating early-stage life sciences companies with breakthrough technologies and discovery capabilities that have the potential to address unmet medical needs and improve patients’ quality of life globally. The firm currently manages three U.S. dollar-denominated funds and one RMB-denominated fund.
